Literature DB >> 18766142

Secondary-progressive form of multiple sclerosis: MRI changes versus clinical status.

Martin Masek1, Manuela Vaneckova, Jan Krasensky, Jan Danes, Eva Havrdova, Tereza Hrebikova, Zdenek Seidl.   

Abstract

OBJECTIVES: To monitor the interaction between the clinical manifestation of the secondary progressive form of multiple sclerosis (SPMS) expressed in the Expanded Disability Status Scale (EDSS) and abnormal findings in magnetic resonance imaging (MRI) of the brain. To compare a time line of brain atrophy in patients with SPMS, patients with relapsing-remitting multiple sclerosis (RRMS) and the healthy population.
METHODS: Brain atrophy, volume of increased signal lesions on Fluid Attenuated Inversion Recovery Sequence (FLAIR) sequence (s.c.lesion load) and decreased signal lesions on T1 weighted sequence (s.c. black holes) were measured semi-automatically and correlated with EDSS in 12 patients. Further, we compared a time line of brain parenchyma fraction (BPF) loss in patients with SPMS, patients with RRMS and the healthy population.
RESULTS: In patients with SPMS, no statistical correlation was found between lesion load in FLAIR and EDSS and there was also no significant statistical correlation (p=0.1134) between the volume of "black holes" and EDSS. However, we did confirm a significant correlation between increase in brain atrophy and clinical status (p=0.0093). Comparison of patients with SPMS or RRMS and the healthy population revealed that brain atrophy progressed most rapidly in patients with SPMS.
CONCLUSIONS: The presence of a statistically significant difference in BPF loss between patients with SPMS or RRMS and the healthy population merits further study despite the small size of our sample. We postulate that the measurement of brain atrophy could be helpful in determining the transition of RRMS to SPMS and thereby predict the progression of the disease in the future.

Entities:  

Mesh:

Year:  2008        PMID: 18766142

Source DB:  PubMed          Journal:  Neuro Endocrinol Lett        ISSN: 0172-780X            Impact factor:   0.765


  7 in total

1.  Intracortical excitability in patients with relapsing-remitting and secondary progressive multiple sclerosis.

Authors:  A Conte; D Lenzi; V Frasca; F Gilio; E Giacomelli; M Gabriele; C Marini Bettolo; E Iacovelli; P Pantano; C Pozzilli; M Inghilleri
Journal:  J Neurol       Date:  2009-03-01       Impact factor: 4.849

Review 2.  A focus on secondary progressive multiple sclerosis (SPMS): challenges in diagnosis and definition.

Authors:  Hernan Inojosa; Undine Proschmann; Katja Akgün; Tjalf Ziemssen
Journal:  J Neurol       Date:  2019-07-30       Impact factor: 4.849

Review 3.  The Role of T1-Weighted Derived Measures of Neurodegeneration for Assessing Disability Progression in Multiple Sclerosis.

Authors:  Maria A Rocca; Giancarlo Comi; Massimo Filippi
Journal:  Front Neurol       Date:  2017-09-04       Impact factor: 4.003

Review 4.  Evolving Landscape of Multiple Sclerosis in India: Challenges in the Management.

Authors:  Sudhir Kumar; Anshu Rohatgi; Harshal Chaudhari; Priti Thakor
Journal:  Ann Indian Acad Neurol       Date:  2018 Apr-Jun       Impact factor: 1.383

Review 5.  Should We Use Clinical Tools to Identify Disease Progression?

Authors:  Hernan Inojosa; Undine Proschmann; Katja Akgün; Tjalf Ziemssen
Journal:  Front Neurol       Date:  2021-01-21       Impact factor: 4.003

6.  The Application of Diffusion Kurtosis Imaging on the Heterogeneous White Matter in Relapsing-Remitting Multiple Sclerosis.

Authors:  Qiyuan Zhu; Qiao Zheng; Dan Luo; Yuling Peng; Zichun Yan; Xiaohua Wang; Xiaoya Chen; Yongmei Li
Journal:  Front Neurosci       Date:  2022-03-10       Impact factor: 4.677

7.  Correlation between the clinical disability and T1 hypointense lesions' volume in cerebral magnetic resonance imaging of multiple sclerosis patients: A systematic review and meta-analysis.

Authors:  Amir Valizadeh; Mana Moassefi; Elham Barati; Mohammad Ali Sahraian; Faezeh Aghajani; Mohammad-Reza Fattahi
Journal:  CNS Neurosci Ther       Date:  2021-10-03       Impact factor: 5.243

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.